KR20120003278A - Sustained-release pharmaceutical composition comprising pramipexole or pharmaceutically acceptable salt thereof having improved stability - Google Patents

Abstract

PURPOSE: A sustained release pharmaceutical composition containing pramipexole is provided to ensure effectively controlled release and to minimize impurity. CONSTITUTION: A sustained release pharmaceutical composition contains 0.0005-0.025 wt% of pramipexole or pharmaceutically acceptable salt thereof as an active ingredient and pharmaceutically acceptable excipient. The composition also contains 20-50 wt% of hydroxypropyl methyl cellulose and 1-8 wt% of methacryl cationic polymers. The methacryl cationic polymers are poly(butyl methacrylate, (2-dimethylaminoethyl)methacrylate, methyl methacrylate) polymer.

Description

Sustained-release pharmaceutical composition with improved stability comprising pramipexole or a pharmaceutically acceptable salt thereof {SUSTAINED-RELEASE PHARMACEUTICAL COMPOSITION COMPRISING PRAMIPEXOLE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF HAVING IMPROVED STABILITY}

The present invention relates to a sustained-release pharmaceutical composition comprising pramipexole or a pharmaceutically acceptable salt thereof, and more particularly, by using a stabilizer, it is possible to suppress the generation of a flexible substance by an additive, thereby greatly improving stability. It relates to a pharmaceutical composition.

Pramipexole is a known dopamine D2 receptor agonist and is useful for the treatment of schizophrenia and Parkinson's disease. It is structurally different from ergot-derived drugs such as bromocriptine or pergolide, and has receptor selectivity for dopamine receptors in the dopamine D2 group and is a complete agent. Pharmacologically unique in that respect.

Pramipexole which can be represented by the following formula (1) is (S) -2-amino-4,5,6,7-tetrahydro-6- (propylamino) having the molecular formula C ₁₀ H ₁₇ N ₃ S, relative molar mass 211.33 Benzothiazole.

Pramipexole or its salt raw material itself has excellent stability at room temperature, while stability is reduced when exposed to light and moisture. In particular, there is a problem to increase the generation of flexible material is very sensitive to moisture. In addition, European EMEA data indicate that pramipexole generic tablets (Mirapexin) and pramipexole sustained-release tablets (Mirapexin prolonged-release tablets) are very sensitive to moisture, which may occur during the distribution of products through special packaging. The problem is minimized.

In general, in order to always exhibit a certain effect, pharmaceuticals must not only decrease the content of the active ingredient immediately after the manufacture of the product but also during the storage period, and also increase the decomposition products, that is, impurities or soft substances, of the active ingredient during the same period. Should be kept to a minimum. Therefore, preventing the incorporation of impurities in the drug is very important for drug quality control. If you look at the regulations of each country's process for purity test, Korea Pharmacopoeia sets a flexible substance separately in the purity test term, and the US Pharmacopoeia defines 'Ordinary impurities'. The amount is set at 2.0% or less, or each group of pharmaceuticals regulates the amount of each related substance by related compounds and chromatographic purity. The European Pharmacopoeia and the British Pharmacopoeia define related substances, while the Japanese Pharmacopoeia regulate them as related substances during purity testing.

As such, the management of impurities contained in pharmaceuticals is a very important issue that enacts a common treaty not only nationally but also internationally.

Therefore, in order to improve the stability of pramipexole-containing formulations, it is very important to select an appropriate excipient, but stabilizing agents applicable to sustained release formulations requiring continuous release have not been properly studied.

Accordingly, the present invention has been made to solve the problems of the prior art, an object of the present invention to provide a pharmaceutical composition that greatly improves the stability by suppressing the generation of the flexible material.

In order to achieve the above object, the present invention provides a sustained-release pharmaceutical formulation comprising an active ingredient including an effective amount of pramipexole or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable excipient including a sustained-release agent and a stabilizer. To provide a composition.

Hereinafter, the pharmaceutical composition and its preparation method according to an embodiment of the present invention will be described in detail.

According to one embodiment of the invention there is provided a sustained release pharmaceutical composition comprising an pharmaceutically acceptable excipient comprising an active ingredient comprising an effective amount of pramipexole or a pharmaceutically acceptable salt thereof, a sustained release base and a stabilizer.

The pramipexole or a pharmaceutically acceptable salt thereof includes pramipexole and racemates, enantiomers, isomers, hydrates, and solvates thereof.

Preferably, (S) -2-amino-4,5,6,7-tetrahydro-6- (propylamino) -benzothiazole, which is an S-enantiomer of pramipexole, may be used. .

As the pharmaceutically acceptable salt of pramipexole, it is preferable to use salts showing moderate to high water solubility. For example hydrochloric acid, hydrobromic acid, hydroiodic acid, phosphoric acid, sulfuric acid, methanesulfonic acid, ethanesulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, p-hydroxybenzoic acid, toluenesulfonic acid, formic acid, acetic acid, propionic acid, benzoic acid, anthranilic acid, tartaric acid , Maleic acid, malic acid, citric acid, iso citric acid, succinic acid, ascorbic acid, lactic acid, glycolic acid, gluconic acid, glucuronic acid, pyruvic acid, oxaloacetic acid, fumaric acid, aspartic acid, glutamic acid, stearic acid, salicylic acid, phenylacetic acid, mannic acid Preparations made with delic acid, pamoic acid, pantothenic acid, sulfanilic acid, cyclohexylaminosulfonic acid, algenic acid, β-hydroxybutyric acid, galactaric acid and galacturonic acid, preferably dihydrochloride salts, most preferred Preferably in the form of dihydrochloride monohydrate.

The effective amount means a content suitable for the treatment or prevention of a disease, which is the type of disease, the severity of the disease, the type and amount of the active ingredient and other ingredients contained in the composition, the type of formulation and the age, weight, general health of the patient. , Sex and diet, time of administration, route of administration and rate of composition, duration of treatment, and drugs used concurrently. For example, when the subject is an adult, the pharmaceutical composition of the present invention may be administered or dosed in an effective amount of a total of 1 to 10 mg when administered or dosed once or several times a day. However, it will be apparent to those skilled in the art that the dosage or dosage of each active ingredient should be such that the content of each active ingredient is too high so as not to cause side effects.

Preferably, pramipexole or a pharmaceutically acceptable salt thereof may be included in an amount of 0.0005 to 0.025% by weight based on the total pharmaceutical composition.

The sustained release base is not particularly limited, and for example, hydroxypropyl methyl cellulose (HPMC, or hypromellose), hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), carboxymethyl cellulose (CMC), and the like. Hydrophilic polymers such as cellulose, xanthan gum, sodium alginate, polyethylene oxide, and crosslinked homopolymers and copolymers of acrylic acid and the like and mixtures thereof can be used.

Preferably HPMC (Hypromellose), namely HPMC 2910 (E3, E5, E6, E15, E50, E4M, E10M), HPMC 2906 (F50, F4M), HPMC 2208 (K3, K100, K4M, K15M, K100M ) Or mixtures thereof.

Preferably the HPMC may be included in 20 to 50% by weight based on the total pharmaceutical composition. If the drug is less than the above range, the drug release rate is increased, which causes side effects due to dose dumping, etc., which is not preferable. If the drug release rate is exceeded, the drug release rate is slowed to reach the optimal blood concentration. It is not preferable because there is a problem that does not exhibit sufficient efficacy.

The pharmaceutical composition according to the embodiment of the present invention includes a pharmaceutically acceptable excipient including a stabilizer.

Preferably the stabilizer is a hydroxypropylcellulose having a hydroxypropoxy content of 7.0 to 15.0% and / or a methacrylic cationic polymer that is dissolved in a solution of pH 5.5 or below.

The hydroxypropyl cellulose having a hydroxypropoxy content of 7.0 to 15.0% is also referred to as low-substituted hydroxypropyl cellulose (L-HPC), and is represented by the following Chemical Formula 2.

Wherein R is -H or -CH ₂ CH (CH ₃ ) OH (see Alvarez-Lorenzo et al, 2000).

L-HPC is a low-substituted hydroxypropyl ether of cellulose that contains very small amounts of hydroxypropoxy groups in the beta-o-glucopyranosyl ring of cellulose and is highly substituted (glucose). The average number of hydroxypropoxy groups per ring unit, i.e. molar substitution of 3 to 5) While hydroxypropyl ether is soluble in both water and alcohol, L-HPC (molar substitution) Is 0.2 to 0.4) and swell without dissolving in water. L-HPC is classified according to Table 1 according to the substitution level and particle size.

Rating
(grade) Hydroxypropoxy content (%) Average particle size
(um) Bulk (g / cm3) Tapped Density (g / cm3) LH-11 10.0 to 12.9 45-65 0.32 0.56 LH-21 10.0 to 12.9 35-55 0.36 0.62 LH-31 10.0 to 12.9 20-30 0.28 0.59 LH-22 7.0 to 9.9 35-55 0.36 0.62 LH-32 7.0 to 9.9 20-30 0.28 0.59 LH-20 13.0-15.0 35-55 0.36 0.62 LH-30 13.0-15.0 20-30 0.28 0.59

LH-11 has moderate substitution levels and the largest particle size. It is used as an anti-capping agent and disintegrant in the tableting method. LH-21 is used as a binder and disintegrant in forming tablets by wet granulation. LH-31 has a small particle size suitable to pass through the net and therefore is particularly used for extrusion to form granules. LH-22 and LH-32 can be used when strong bonding strength is not required and LH-20 and LH-30 can be used when strong bonding strength is required. As such, the degree of substitution of L-HPC and the change in particle size result in a change in bonding and disintegration properties as a result of subtle changes in physical properties. Therefore, the above-mentioned various low-substituted hydroxypropyl cellulose can be appropriately selected and used according to each application type, and preferably, a hydroxypropoxy content of 7.0 to 9.9% can be used.

On the other hand, the L-HPC is generally a disintegrating excipient (disintegrant or binder), when contained in the sustained release base, when exposed in vivo, the voids around the sustained release base is generated to control the drug release There is a disadvantage that can be difficult in the prior art has not been used in the sustained release formulation.

However, our experiments have surprisingly found that by appropriate combination of sustained-release mechanisms such as HPMC and stabilizers such as low-substituted hydroxypropyl cellulose, these disadvantages can be overcome and a composition having excellent stability to moisture can be prepared. It was confirmed that there is.

The low-substituted hydroxypropyl cellulose (L-HPC) may preferably comprise 10 to 80% by weight, more preferably 20 to 60% by weight based on the total pharmaceutical composition. Also preferably, the weight ratio of the sustained release base: L-HPC may be 1: 0.2 to 4.

If it is less than the above-mentioned range, the expansion of the sustained release base is lowered, so that the dissolution rate is lowered, and if it is exceeded, micropores on the surface of the base are generated or expanded when the sustained release base is exposed in vivo. ) Is not desirable due to the problem of unexpected release pattern.

As the stabilizer may also be used a methacrylic cationic polymer dissolved in a solution of pH 5.5 or less.

Anionic acrylic polymers such as carbomer, Carbopol® such as Carbomer 941 (Carbopol®71G, Carbopol®971P) and Carbomer 934P (Carbopol®974P, Carbopol®934P) The pH-dependent release may cause the release rate of the sustained release preparation to be varied depending on the food environment by the food, and the release of excess drug is instantaneously released because the stable matrix form cannot be maintained continuously above pH 4.5. Dos dumping may occur. Therefore, the methacrylic cationic polymer which dissolves only in the solution below pH 5.5 is preferable.

The methacrylic cationic polymer is not particularly limited, but is preferably poly (butyl methacrylate, (2-dimethylaminoethyl) methacrylate, methyl methacrylate) 1: 2: 1 Poly (butyl methacrylate, (2-dimethylaminoethyl) methacrylate, methyl methacrylate) 1: 2: 1) Polymers (trade names: Eudragit E, Ro¨hm GmbH) may be used.

Wherein R 1 and R 3 are CH ₃ , R ₂ is CH ₂ CH ₂ N (CH ₃ ) ₂ , and R 4 is CH ₃ or C ₄ H ₉ .

Eudragit E is a cationic polymer based on dimethylaminoethyl methacrylate and other neutral methacrylic acid esters and is used as a gastric coating agent as a dissolution aid for low solubility drugs because it dissolves only below pH 5.5 in a pH dependent manner. They confirmed that the use of Eudragit E not only enables efficient dissolution control of pramipexole sustained release formulations, but also significantly improves stability.

Preferably the methacrylic cationic polymer may be included in 1 to 8% by weight, more preferably 1 to 5% by weight based on the total pharmaceutical composition. If it is less than the above range, the sustained release in the biological solution of pH 5.0 or more can not be secured early dissolution can be completed, the inhibitory effect of the generation of flexible substances can be reduced, if exceeding the above range, the dissolution can be excessively delayed Not desirable

Therefore, by adjusting the amount of the methacrylic cationic polymer according to the above range, the dissolution profile can be changed as desired, and the stability of the pharmaceutical composition of the present invention can be further improved.

Also preferably, the stability may be further improved by including the low-substituted hydroxypropyl cellulose (L-HPC) and the methacrylic cationic polymer together as the stabilizer.

Preferably, the stabilizer may include the hydroxypropyl cellulose and the methacrylic cationic polymer in a weight ratio of 1.25: 1 to 40: 1.

In addition, the pharmaceutical compositions of the present invention may optionally contain microcrystalline cellulose, lactose, glucose, mannitol, alginate, alkaline earth metal salts, clays, diluents such as polyethylene glycol and dicalcium phosphate, glidants such as magnesium stearate or silicon dioxide, and microcrystalline cellulose. Or other conventional excipients such as binders such as starch and the like, and these pharmaceutically acceptable excipients are not particularly limited and may be appropriately selected and used according to techniques known in the art.

The pharmaceutical composition according to the present invention can be utilized to prepare various forms of pramipexole-containing sustained-release formulations having an easily controlled dissolution profile and easy release control, and drug-containing products in storage by using a stabilizer together It is possible to minimize the generation rate of impurities, thereby significantly improving the chemical stability, thereby eliminating the need to conduct separate studies on the physicochemical structural analysis and / or toxicological effects of the impurities.

1 shows the results of stability evaluation by L-HPC according to Experimental Example 1 of the present invention.
Figure 2 shows the results of stability evaluation by Eudragit E according to Experimental Example 2 of the present invention.
Figure 3 shows the dissolution control evaluation results according to Experimental Example 3 of the present invention.

Hereinafter, the present invention will be described in more detail with reference to preferred embodiments. However, the following examples are merely to illustrate the present invention is not limited to the scope of the present invention.

Example  1 and Comparative example  1 to 3: L- HPC Preparation of sustained-release pharmaceutical composition containing

To sustained-release pharmaceutical composition containing pramipexole in accordance with the ingredients and contents of Table 2 was prepared in the form of tablets. That is, after mixing all components except pramipexole and magnesium stearate, finally, magnesium stearate was mixed to prepare tablets and tableted on a rotary tablet press.

mg / tablet Example 1 Comparative Example 1 Comparative Example 2 Comparative Example 3 Pramipexole 0.75 0.75 0.75 0.75 Hydroxypropylmethylcellulose K15M 157.5 157.5 157.5 157.5 Cabopol 71G 14 14 14 14 Low Substituted Hydroxypropyl Cellulose (LH-22) 174.6 - - - Corn starch - 174.6 - - Pregelatinized Starch (Starch 1500) - - 174.6 - Microcrystalline cellulose (AVICEL PH102) - - - 174.6 Colloidal silicon dioxide 1.4 1.4 1.4 1.4 Magnesium stearate 1.75 1.75 1.75 1.75

* As Comparative Example 1, a composition of pramipexole sustained-release tablet (trade name: Mirapexin Prolonged-release tablets) currently commercially available in Europe, as shown in the Patent Publication (10-2007-7005700), was used.

Example  2 and Example  3: Eudragit  Preparation of a sustained release pharmaceutical composition further comprising E

To sustained-release pharmaceutical composition containing pramipexole in accordance with the ingredients and contents of Table 3 below was prepared in the form of tablets. That is, pramipexole was distributed using hydroxypropylmethylcellulose, all components except magnesium stearate were mixed, and finally, magnesium stearate was mixed to prepare tablets and tableted on a rotary tablet press.

mg / tablet Example 2 Example 3 Pramipexole 0.75 0.75 Hydroxypropylmethylcellulose K15M 157.5 157.5 Low Substituted Hydroxypropyl Cellulose (LH-22) 174.6 174.6 Eudragit EPO 14 - Tromethamine - 14 Colloidal silicon dioxide 1.4 1.4 Magnesium stearate 1.75 1.75

Example  4: Pramipexole  Preparation of Sustained-Release Pharmaceutical Compositions

To sustained-release pharmaceutical composition containing pramipexole in accordance with the ingredients and contents of Table 4 below was prepared in the form of tablets. That is, pramipexole was distributed using hydroxypropylmethylcellulose, and then all components except magnesium stearate were mixed, and finally, magnesium stearate was mixed to prepare tablets and tableted on a rotary tablet press.

mg / tablet Example 4 Pramipexole 0.75 Hydroxypropylmethylcellulose K15M 157.5 Low Substituted Hydroxypropyl Cellulose (LH-22) 114.6 Microcrystalline cellulose 74 Eudragit EPO 3 Colloidal silicon dioxide 1.4 Magnesium stearate 1.75

Experimental Example  1: L- HPC On by Pramipexole  Evaluation of the stability of the sustained release pharmaceutical composition

The tablets prepared in Example 1 and Comparative Examples 1 to 3 were subjected to harsh tests under open conditions (completely exposed without packaging) under 40 ° C. and 75% relative humidity, and high speed liquid chromatography every week. Impurity content was analyzed by the method, and the results are shown in FIG. 1.

As can be seen in Figure 1, Example 1 according to the present invention was found to have the lowest rise for the impurities compared to Comparative Examples 1 to 3. Therefore, in the sustained-release pharmaceutical composition containing pramipexole or a salt thereof, when the stabilizer such as low-substituted hydroxypropyl cellulose is used, the storage stability of the pramipexole sustained-release pharmaceutical composition is greatly increased by suppressing the generation of the flexible substance. It was found that it can be improved.

Experimental Example  2: Eudragit  By E Pramipexole  Evaluation of the stability of the sustained release pharmaceutical composition

The tablets prepared in Example 2 and Example 3 were subjected to stability tests in the same manner as in Experimental Example 1, and the results are shown in FIG. 2.

As can be seen in Figure 2, Example 2 according to the present invention showed a result that the production rate of the flexible material is significantly lower than in Example 3, it is much lower than in the case of Example 1 shown in Figure 1, the same Even the methacryl-based polymer can increase the stability according to the ionic characteristics, especially when Eudragit E in combination with low-substituted hydroxypropyl cellulose was confirmed that the stability can be further improved.

Experimental Example  3: Eudragit  Elution Control Evaluation by E

The dissolution profile of pramipexole sustained release tablets prepared in Example 4 was evaluated in standard in vitro Korean Pharmacopoeia dissolution test method and shown in FIG. 3. Specifically, the eluate (900 mL of 0.05 M phosphate buffer (pH 6.8)) was stirred at a rotational speed of 50 rpm and a temperature of 37 ° C. using the paddle method in the KEPCO dissolution test. As can be seen in Figure 3, the drug release rate of pramipexole-containing sustained-release tablets were confirmed to exhibit good sustained release in the amount of Eudragit E.

Claims (9)

A sustained release pharmaceutical composition comprising an active ingredient comprising an effective amount of pramipexole or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient comprising a sustained release base and stabilizer.
The method of claim 1,
Sustained release pharmaceutical composition comprising the pramipexole or a pharmaceutically acceptable salt thereof in an amount of 0.0005 to 0.025% by weight based on the total pharmaceutical composition.
The method of claim 1,
The sustained-release agent is one or more sustained-release pharmaceuticals selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, xanthan gum, sodium alginate, polyethylene oxide and mixtures thereof. Composition.
The method of claim 3,
Sustained release pharmaceutical composition comprising the hydroxypropyl methyl cellulose 20 to 50% by weight based on the total pharmaceutical composition.
The method of claim 1,
The stabilizer is a sustained-release pharmaceutical composition is a hydroxypropyl cellulose having a hydroxypropoxy content of 7.0 to 15.0% or a methacryl-based cationic polymer dissolved in a solution of pH below 5.5.
The method of claim 5,
The methacrylic cationic polymer is a poly (butyl methacrylate, (2-dimethylaminoethyl) methacrylate, methyl methacrylate) 1: 2: 1 polymer.
The method of claim 5,
Sustained release pharmaceutical composition comprising the hydroxypropyl cellulose in 10 to 80% by weight based on the total pharmaceutical composition.
The method according to claim 5 or 6,
Sustained-release pharmaceutical composition comprising the methacrylic cationic polymer in an amount of 1 to 8% by weight based on the total pharmaceutical composition.
The method of claim 1, wherein the stabilizer,
A sustained-release pharmaceutical composition which is a hydroxypropyl cellulose having a hydroxypropoxy content of 7.0 to 15.0% and a methacrylic cationic polymer dissolved in a solution of pH 5.5 or less.

Images